Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2018
1-4 issues

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2007, No. 3

Subscribe for 2019 year

Order this issue

Order PDF of this article

Practitioner Advisor

Number 3'2007

THE INFLUENCE OF BESTIM (SCV-07) ON T-CELL DIFFERENTIATION IN MICE

A.V. Petrov, N.V. Pigareva, A.Yu. Kotov, A.A. Kolobov, A.S. Simbirtsev

SCV-07 is a novel immunomodulatory drug used for treatment of secondary immune deficiencies. Here we provide data which show that in mice SCV-07 stimulates lymphopoesis, increase of c-kit+ and Thy1+ cells in the bone marrow, and causes changes in subpopulations of thymocytes accompanied by increased proliferation capacity and cytokine production by these cells. Administration of SCV-07 also increases IL-2 and IFNγ production by mitogen stimulated spleen cells while IL-4 production remains unchanged or is reduced indicating a shift of the immune response towards Th1 phenotype. When administered per os SCV-07 completely retains its immunomodulatory activity. Together these data suggest that SCV-07 is a promising drug for treatment of numerous diseases which are accompanied by T cell deficiency or mediated by impaired Th1/Th2 balance. (Cytokines and Inflammation. 2007. Vol. 6, No. 3. P. 27-31.)

Keywords: SCV-07, T lymphocyte, differentiation, cytokines.

Contents | Next article | Previous article


© 2007-2019 Cytokines and inflammation